Investment signal Recent funding round and ongoing growth indicate increased capacity for customer acquisition and larger project scopes. Target biotech labs, contract research organizations, and manufacturing teams that require scalable, rapid biomolecular analysis to accelerate development timelines.

In-solution advantage Fidabio’s in-solution, surface-free measurements address common binding artifacts and enable direct characterization in complex matrices. This presents a compelling value proposition to pharmaceutical and biotech teams working with plasma, serum, cell lysates, or fermentation broths, reducing assay development time.

Platform capabilities Absolute measurements of hydrodynamic radius, affinity, kinetics, stoichiometry, and conformational changes enable comprehensive profiling of proteins, antibodies, exosomes, liposomes, and membrane proteins. Upsell opportunities exist with projects spanning binding studies, stability assessment, and quality control during manufacturing.

Market alignment The company sits in a mid-market niche with growth potential alongside larger CROs and specialty biotech firms seeking rapid, matrix-tolerant analyses. Strategic outreach to mid-sized biotech startups expanding into protein therapeutics or nanoparticle-based diagnostics could yield early adoption customers.

Growth indicators Strong revenue signals paired with notable external funding suggest readiness to scale sales; prioritize multi-site and cross-region outreach, partner ecosystems, and reference customers to demonstrate track record and drive larger, longer-term contracts.